{
    "clinical_study": {
        "@rank": "20109", 
        "arm_group": {
            "arm_group_label": "Aurora Treatment Arm", 
            "arm_group_type": "Experimental", 
            "description": "Endometrial Ablation"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, single-arm, non-randomized, prospective clinical study.  The\n      clinical study is designed as a non-inferiority study to assess the effectiveness of the\n      Aurora Endometrial Ablation System compared to an objective standard.  Safety will be\n      evaluated by determining the number and percentage of subjects who experience one or more of\n      serious adverse events."
        }, 
        "brief_title": "A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA\u2122 Endometrial Ablation System", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Menorrhagia Due to Benign Causes", 
        "condition_browse": {
            "mesh_term": "Menorrhagia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Refractory menorrhagia with no definable organic cause\n\n          2. Female subject from age 25 to 50 years\n\n          3. Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)\n\n          4. One of the following criteria:\n\n             A. Documented history of menorrhagia secondary to dysfunctional uterine bleeding\n             (DUB).\n\n             B. If a pictorial blood loss assessment chart (PBLAC) scoring systems is used; a\n             minimum PBLAC score of \u2265150 for 1 month prior to study enrollment; C. If AH system is\n             used a minimum of 160ml/blood loss for 1 month prior to study enrollment\n\n          5. Premenopausal at enrollment as determined by FSH measurement \u2264 40 IU/ml\n\n          6. Not pregnant and no desire to be pregnant in the future\n\n          7. Patient agrees not to use hormonal contraception or any other medical intervention\n             for bleeding during the study\n\n          8. Able to provide written informed consent using a form that has been approved by the\n             reviewing IRB/EC\n\n          9. Subject agrees to follow-up exams and data collection, including ability to\n             accurately use menstrual diaries for PBLAC analysis or the collection of used\n             sanitary product for AH analysis\n\n         10. Subject who is literate or demonstrates an understanding on how to use menstrual\n             diaries or how to collect and provide used sanitary products for analysis\n\n        Exclusion Criteria:\n\n          1. Pregnancy or subject with a desire to conceive\n\n          2. Endometrial hyperplasia as confirmed by histology\n\n          3. Presence of active endometritis\n\n          4. Active pelvic inflammatory disease\n\n          5. Active sexually transmitted disease (STD), at the time of ablation. Note: Treatment\n             of STD documented in the chart serves as sufficient evidence of infection resolution.\n             Patient may be considered for study enrollment.\n\n          6. Presence of bacteremia, sepsis, or other active systemic infection\n\n          7. Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time\n             of the procedure\n\n          8. Known/suspected gynecological malignancy within the past 5 years\n\n          9. Known clotting defects or bleeding disorders\n\n         10. Untreated/unevaluated cervical dysplasia (except CIN I)\n\n         11. Known/suspected abdominal/pelvic cancer\n\n         12. Prior uterine surgery (except low segment cesarean section) that interrupts the\n             integrity of the uterine wall (e.g., myomectomy or classical cesarean section)\n\n         13. Previous endometrial ablation procedure\n\n         14. Currently on medications that could thin the myometrial muscle, such as long-term\n             steroid use (except inhaler or nasal therapy for asthma)\n\n         15. Currently on anticoagulants\n\n         16. Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:\n\n               1. Septate or bicornuate uterus or other congenital malformation of the uterine\n                  cavity\n\n               2. Pedunculated or submucosal myomas distorting the uterine cavity\n\n               3. Polyps likely to be the cause of the subject's menorrhagia\n\n               4. Intramural or subserosal myomas that distort the uterine cavity\n\n         17. Presence of an intrauterine device (IUD) which the patient is unwilling to have\n             removed at the time of the operative visit\n\n         18. Presence of an implantable contraceptive device (e.g. Essure or Adiana).\n\n         19. Subject currently on hormonal birth control therapy or unwilling to use a\n             non-hormonal birth control post-ablation (including a Mirena device).\n\n         20. Subject who is within 6-weeks post partum.\n\n         21. Any general health condition which, in the opinion of the Investigator, could\n             represent an increased risk for the subject\n\n         22. Any subject who is currently participating or considers future participation in any\n             other research of an investigational drug or device."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029911", 
            "org_study_id": "CIP0003"
        }, 
        "intervention": {
            "arm_group_label": "Aurora Treatment Arm", 
            "description": "Ablation of the endometrial lining of the uterus using the Aurora System", 
            "intervention_name": "Aurora Endometrial Ablation System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Menorrhagia", 
            "Excessive uterine bleeding", 
            "Endometrial Ablation"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Montr\u00e9al", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H4J 1C5"
                    }, 
                    "name": "H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ville Lassalle", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H8P 1C1"
                    }, 
                    "name": "H\u00f4pital Lasalle"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1W 2J5"
                    }, 
                    "name": "La Cite Medicale"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA\u2122 Endometrial Ablation System", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Canada: Ethics Review Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Uterine bleeding as measured by Alkaline Hematin or Pictorial Blood Loss Assessment Chart (PBLAC) post-treatment", 
                "measure": "Uterine Bleeding", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "The primary safety endpoint is the occurrence of adverse events.", 
                "measure": "Occurrence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029911"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subject satisfaction and response to subject questionnaires.", 
            "measure": "Long-Term Subject Follow-up", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Minerva Surgical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Minerva Surgical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}